|1.||Sugita, Kanji: 1 article (10/2011)|
|2.||Kanemura, Hideaki: 1 article (10/2011)|
|3.||Aihara, Masao: 1 article (10/2011)|
|4.||Sano, Fumikazu: 1 article (10/2011)|
|5.||Yoshimura, Kuniko: 1 article (03/2005)|
|6.||Hayashi, Izumi: 1 article (03/2005)|
|7.||Nishikawa, Takashi: 1 article (03/2005)|
|8.||Soma, Kazui: 1 article (03/2005)|
|9.||Kamijo, Yoshito: 1 article (03/2005)|
|10.||Onozawa, K: 1 article (12/2001)|
|1.||Neurotic Disorders (Neuroses)
10/01/2011 - "We evaluated the safety and efficacy of ethyl loflazepate in children with epilepsy. "
10/01/2011 - "Ethyl loflazepate represents an important addition to the treatments available for refractory epilepsies in children."
10/01/2011 - "Effects of ethyl loflazepate on refractory epilepsy in children."
|3.||Renal Insufficiency (Renal Failure)
01/01/1989 - "These results indicate the absence of a risk of accumulation of the 2 main and active metabolites of ethyl loflazepate in patients with renal failure."
01/01/1989 - "The kinetics of ethyl loflazepate were studied in patients with various degrees of renal failure. "
01/01/1989 - "Effect of renal failure on the pharmacokinetics of ethyl loflazepate (Victan) in man."
|4.||Ganglion Cysts (Ganglion)
12/01/1997 - "Antiemetic effect and safety of concurrent administration of ondansetron and other antiemetics (dexamethasone, domperidone and ethyl loflazepate), given for complete suppression of nausea/vomiting, were examined in 46 patients (109 courses) with gynecological cancer receiving single high-dose of cisplatin or carboplatin. "
|9.||Dihydrotachysterol (AT 10)